-
Je něco špatně v tomto záznamu ?
Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE
RL. Benza, PA. Corris, JR. Klinger, D. Langleben, R. Naeije, G. Simonneau, HA. Ghofrani, P. Jansa, S. Rosenkranz, L. Scelsi, T. Thenappan, A. Raina, C. Meier, D. Busse, MM. Hoeper
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- inhibitory fosfodiesterasy 5 * MeSH
- lidé MeSH
- pilotní projekty MeSH
- plicní hypertenze * farmakoterapie MeSH
- pyrazoly MeSH
- pyrimidiny MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: RESPITE evaluated patients with pulmonary arterial hypertension and an inadequate response to phosphodiesterase type 5 inhibitors (PDE5i) who switched to riociguat. This post hoc analysis assessed response to this switch in parameters associated with clinical improvement. METHODS: RESPITE was a 24-week, uncontrolled pilot study (n = 61). Differences in functional, hemodynamic, and cardiac function parameters, REVEAL risk score (RRS), and biomarkers were compared between responders (free from clinical worsening, World Health Organization functional class I/II, and ≥30 m improvement in 6-min walking distance at Week 24) and non-responders. RESULTS: Of 51 patients (84%) completing RESPITE, 16 (31%) met the responder endpoint. At baseline, there were significant differences between responders and non-responders in N-terminal prohormone of brain natriuretic peptide (NT-proBNP), growth/differentiation factor 15 (GDF-15), and RRS, whereas there were no differences in hemodynamics or cardiac function. At Week 24, responders had significant improvements in pulmonary arterial compliance, pulmonary vascular resistance, and mean pulmonary arterial pressure, while non-responders showed no significant change. Cardiac efficiency and stroke volume index significantly improved irrespective of responder status. CONCLUSIONS: NT-proBNP, GDF-15, and RRS were identified as potential predictors of response in patients switching from PDE5i to riociguat. Further prospective controlled studies are needed to confirm the association of these parameters with response.
Chrestos Concept GmbH and Co KG Essen Germany
Clinic 3 for Internal Medicine University of Cologne Cologne Germany
Cologne Cardiovascular Research Center University of Cologne Cologne Germany
Department of Cardiology Erasme University Hospital Brussels Belgium
Department of Medicine Imperial College London London UK
Division of Cardiology University of Minnesota Minneapolis MN USA
Division of Cardiovascular Medicine The Ohio State University Wexner Medical Center OH USA
Institute of Cellular Medicine Newcastle University Newcastle upon Tyne UK
The Cardiovascular Institute Allegheny General Hospital Pittsburgh PA USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019981
- 003
- CZ-PrNML
- 005
- 20210830101559.0
- 007
- ta
- 008
- 210728s2020 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijcard.2020.05.044 $2 doi
- 035 __
- $a (PubMed)32461118
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Benza, Raymond L $u Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, OH, USA. Electronic address: Raymond.benza@osumc.edu
- 245 10
- $a Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE / $c RL. Benza, PA. Corris, JR. Klinger, D. Langleben, R. Naeije, G. Simonneau, HA. Ghofrani, P. Jansa, S. Rosenkranz, L. Scelsi, T. Thenappan, A. Raina, C. Meier, D. Busse, MM. Hoeper
- 520 9_
- $a BACKGROUND: RESPITE evaluated patients with pulmonary arterial hypertension and an inadequate response to phosphodiesterase type 5 inhibitors (PDE5i) who switched to riociguat. This post hoc analysis assessed response to this switch in parameters associated with clinical improvement. METHODS: RESPITE was a 24-week, uncontrolled pilot study (n = 61). Differences in functional, hemodynamic, and cardiac function parameters, REVEAL risk score (RRS), and biomarkers were compared between responders (free from clinical worsening, World Health Organization functional class I/II, and ≥30 m improvement in 6-min walking distance at Week 24) and non-responders. RESULTS: Of 51 patients (84%) completing RESPITE, 16 (31%) met the responder endpoint. At baseline, there were significant differences between responders and non-responders in N-terminal prohormone of brain natriuretic peptide (NT-proBNP), growth/differentiation factor 15 (GDF-15), and RRS, whereas there were no differences in hemodynamics or cardiac function. At Week 24, responders had significant improvements in pulmonary arterial compliance, pulmonary vascular resistance, and mean pulmonary arterial pressure, while non-responders showed no significant change. Cardiac efficiency and stroke volume index significantly improved irrespective of responder status. CONCLUSIONS: NT-proBNP, GDF-15, and RRS were identified as potential predictors of response in patients switching from PDE5i to riociguat. Further prospective controlled studies are needed to confirm the association of these parameters with response.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a plicní hypertenze $x farmakoterapie $7 D006976
- 650 12
- $a inhibitory fosfodiesterasy 5 $7 D058986
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a pyrazoly $7 D011720
- 650 _2
- $a pyrimidiny $7 D011743
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Corris, Paul A $u Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK
- 700 1_
- $a Klinger, James R $u Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA
- 700 1_
- $a Langleben, David $u Center for Pulmonary Vascular Disease and Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada
- 700 1_
- $a Naeije, Robert $u Department of Cardiology, Erasme University Hospital, Brussels, Belgium
- 700 1_
- $a Simonneau, Gérald $u Assistance Publique-Hôspitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud, Laboratoire d-Excellence en Rescherche sur le Médicament et Innovation Thérapeutique and INSERM Unité 999, Le Kremlin-Bicêtre, France
- 700 1_
- $a Ghofrani, Hossein-Ardeschir $u University of Giessen and Marburg Lung Center, Member of the German Center for Lung Research (DZL), Giessen, Germany; Department of Medicine, Imperial College London, London, UK
- 700 1_
- $a Jansa, Pavel $u Clinical Department of Cardiology and Angiology, 1st Faculty of Medicine, 2nd Medical Department, Charles University, Prague, Czech Republic
- 700 1_
- $a Rosenkranz, Stephan $u Clinic III for Internal Medicine (Cardiology), Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany; Cologne Cardiovascular Research Center (CCRC), University of Cologne, Cologne, Germany
- 700 1_
- $a Scelsi, Laura $u Division of Cardiology, Fondazione Istituto di Ricerca e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy
- 700 1_
- $a Thenappan, Thenappan $u Division of Cardiology, University of Minnesota, Minneapolis, MN, USA
- 700 1_
- $a Raina, Amresh $u The Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, USA
- 700 1_
- $a Meier, Christian $u Bayer AG, Berlin, Germany
- 700 1_
- $a Busse, Dennis $u Chrestos Concept GmbH & Co. KG, Essen, Germany
- 700 1_
- $a Hoeper, Marius M $u Clinic for Respiratory Medicine, Hannover Medical School, member of the German Center for Lung Research (DZL), Hannover, Germany
- 773 0_
- $w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 317, č. - (2020), s. 188-192
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32461118 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830101559 $b ABA008
- 999 __
- $a ok $b bmc $g 1690718 $s 1140427
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 317 $c - $d 188-192 $e 20200524 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
- LZP __
- $a Pubmed-20210728
